Pyxis Oncology, Inc. (PYXS) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.94
↑+126% vs avg
5yr avg: 0.86
30Y Low0.3·High1.4
ROE
↓
-91.4%
↑-41% vs avg
5yr avg: -64.9%
30Y Low-91%·High-52%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PYXS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pyxis Oncology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $106M | $71M | $91M | $72M | $44M | $353M | — | — |
| Enterprise Value | $109M | $75M | $92M | $83M | $-116107671 | $79M | — | — |
| P/E Ratio → | -1.30 | — | — | — | — | — | — | — |
| P/S Ratio | 7.63 | 5.16 | 5.65 | — | — | — | — | — |
| P/B Ratio | 1.94 | 1.34 | 0.76 | 0.57 | 0.28 | 1.35 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PYXS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.39 | 5.69 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
PYXS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Pyxis Oncology, Inc. earns an operating margin of -609.2%. Operating margins have compressed from -554.1% to -609.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -91.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.8% | 82.8% | 97.1% | — | — | — | — | — |
| Operating Margin | -609.2% | -609.2% | -554.1% | — | — | — | — | — |
| Net Profit Margin | -574.5% | -574.5% | -478.9% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -91.4% | -91.4% | -62.8% | -51.5% | -57.2% | -61.9% | — | — |
| ROA | -64.0% | -64.0% | -46.7% | -38.3% | -49.1% | -52.4% | -85.6% | -14.0% |
| ROIC | -71.1% | -71.1% | -51.8% | -89.5% | — | — | — | — |
| ROCE | -80.4% | -80.4% | -62.2% | -50.2% | -56.0% | -52.1% | -101.0% | -15.1% |
PYXS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $3M ($19M total debt minus $15M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.35 | 0.35 | 0.17 | 0.17 | 0.12 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.06 | 0.01 | 0.09 | -1.00 | -1.05 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
PYXS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Pyxis Oncology, Inc.'s current ratio of 3.41x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.84x to 3.41x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | 3.41 | 7.49 | 4.84 | 5.90 | 14.90 | 2.20 | 26.88 |
| Quick Ratio | 3.41 | 3.41 | 7.49 | 4.84 | 5.90 | 14.90 | 2.20 | 26.88 |
| Cash Ratio | 3.16 | 3.16 | 7.18 | 4.63 | 5.67 | 14.69 | 2.19 | 26.86 |
| Asset Turnover | — | 0.15 | 0.10 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 18.44 | — | — | — | — | — | — |
PYXS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pyxis Oncology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $62M | $58M | $40M | $33M | $32M | $34M | $34M |
Peer Comparison
Compare PYXS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PYXSYou | $106M | -1.3 | — | — | 82.8% | -609.2% | -91.4% | -71.1% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 RCUS | $2B | -7.1 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TPST | $6M | -0.2 | — | — | — | — | -203.6% | -352.0% | — |
 AGIO | $2B | -4.0 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 MGNX | $255M | -3.4 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 SNDX | $2B | -5.4 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 FATE | $230M | -1.7 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 AGEN | $141M | -997.1 | — | — | 29.6% | -18.0% | — | — | — |
 PFE | $149B | 19.2 | 10.6 | 16.4 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in PYXS 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in PYXS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PYXS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPYXS vs IMVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Immunovant, Inc..
Compare NowPYXS — Frequently Asked Questions
Quick answers to the most common questions about buying PYXS stock.
What is Pyxis Oncology, Inc.'s P/E ratio?
Pyxis Oncology, Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
What is Pyxis Oncology, Inc.'s ROE?
Pyxis Oncology, Inc.'s return on equity (ROE) is -91.4%. The historical average is -64.9%.
Is PYXS stock overvalued?
Based on historical data, Pyxis Oncology, Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Pyxis Oncology, Inc.'s profit margins?
Pyxis Oncology, Inc. has 82.8% gross margin and -609.2% operating margin.